Could a biologic drug spare patients from repeat throat surgeries?
NCT ID NCT05309616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug Taltz (ixekizumab) in 10 people with idiopathic subglottic stenosis, a rare condition where scar tissue narrows the airway. The goal was to see if blocking IL-17A could slow scar formation and lengthen the time between needed surgeries. Participants received injections over several months, and researchers tracked how long they could avoid repeat procedures.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Taltz (ixekizumab)
- What this could lead to
- If it works, this could reduce or eliminate the need for repeat surgeries in people with idiopathic subglottic stenosis.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drug also carries risks like infections and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
10 people
The number who actually took part.
- Started
-
Feb 2025
- Finished
-
May 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * diagnosis of idiopathic subglottic stenosis Exclusion Criteria: * History of active or latent tuberculosis infection * History of inflammatory bowel disease * Pregnancy or lactation * Known allergic reactions to study drug * Disease involving the vocal cords * Individuals who are taking drugs known to trigger angioedema, including use acquired angioedema from drugs such as ACE inhibitors (e.g. Lisinopril) and nonsteroidal anti-inflammatory drugs (NSAIDs) and individuals with a history of other forms of angioedema such as hereditary and Clesterase deficiency
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic subglottic stenosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.